Haleon PLC Annual Financial Report 2022 and Notice of AGM (5649T)
21 March 2023 - 02:15AM
UK Regulatory
TIDMHLN
RNS Number : 5649T
Haleon PLC
20 March 2023
Annual Financial Report 2022 and Notice of AGM
20 March 2023: Haleon plc (the "Company") (LSE/NYSE: HLN) today
announces that the following documents have been made available to
shareholders:
1. Annual Report and Form 20-F 2022
2. Notice of 2023 Annual General Meeting (AGM)
3. Form of Proxy for the 2023 AGM
4. AGM Voting Instruction Card
A copy of each of the documents has been submitted to the
National Storage Mechanism and will shortly be available for
inspection at
https://data.fca.org.uk/#/nsm/nationalstoragemechanism .
The Company will also file the Annual Report and Form 20-F 2022
with the US Securities and Exchange Commission today.
The documents referred to above are publicly available on the
Company's website at www.haleon.com .
In compliance with the Disclosure Guidance and Transparency
Rules, the Annual Report and Form 20-F 2022, as submitted to the
National Storage Mechanism, contains regulated information in
unedited full text and is available on the Company's website as
noted above.
Shareholders may request a hard copy of the Annual Report and
Form 20-F 2022, including the complete audited financial statements
of the Company, free of charge from: Company Secretariat, Haleon
plc, Building 5, First Floor, The Heights, Weybridge, KT13 0NY,
United Kingdom.
Amanda Mellor, Company Secretary
About Haleon
Haleon (LSE / NYSE: HLN) is a global leader in consumer health,
with a purpose to deliver better everyday health with humanity.
Haleon's product portfolio spans five major categories - Oral
Health, Pain Relief, Respiratory Health, Digestive Health and
Other, and Vitamins, Minerals and Supplements (VMS). Its
long-standing brands - such as Advil, Sensodyne, Panadol, Voltaren,
Theraflu, Otrivin, Polident, parodontax and Centrum - are built on
trusted science, innovation and deep human understanding.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
ACSBUGDXGGDDGXG
(END) Dow Jones Newswires
March 20, 2023 11:15 ET (15:15 GMT)
Haleon (LSE:HLN)
Historical Stock Chart
From Feb 2024 to Mar 2024
Haleon (LSE:HLN)
Historical Stock Chart
From Mar 2023 to Mar 2024